PNT2002

PNT2002 combines a PSMA-specific ligand with the beta-emitting radioisotope lutetium-177.

PNT2002 is currently in a Phase 3 study designed to evaluate superiority to the standard of care in mCRPC patients.

More information about PNT2002's Phase 3 Study For Men With Metastatic Castration-Resistant Prostate Cancer can be found at SplashTrial.com